Skip to Content

Cancer Quality Report

When you're diagnosed with cancer, you want a treatment program recognized for its commitment to providing comprehensive and patient-centered care.

The cancer program at North Kansas City Hospital is accredited by the Commission on Cancer, a program of the American College of Surgeons dedicated to improving survival rates and quality of life for people with cancer.

This accreditation ensures our cancer program meets the highest standards of evidence-based practices and provides quality care to you.

Through the Commission on Cancer, we have access to reporting tools called Cancer Program Practice Profile Reports (CP3R) that help with benchmarking and improving our outcomes. 

The comparisons below are from the Commission on Cancer website and reflect the most current data.

Breast Cancer

Reporting Period: 2017

Radiation is administered within one year of diagnosis for women under age 70 receiving breast-conserving surgery.

NKCH 94%
Region 94%
Missouri 94%
National 92%

Combination chemotherapy is considered or administered within four months of diagnosis for women under 70 with AJCC T1c N0 M0 or Stage 2 or 3 estrogen receptor-negative and progesterone-receptor negative breast cancer.

NKCH 92%
Region 96%
Missouri 95%
National 93%

Tamoxifen or third-generation aromatase inhibitors are considered or administered within one year of diagnosis for women with T1c N0 M0 or Stage 2 or 3 estrogen receptor-positive and/or progesterone-receptor positive breast cancer.

NKCH 97%
Region 97%
Missouri 97%
National 93%

Radiation therapy is considered or administered following any mastectomy within one year of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes.

NKCH 100%
Region 94%
Missouri 97%
National 88%